Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.

By R. Bright, M. Medina, Xiyan Xu, Gilda I. Perez-Oronoz, T. Wallis, X. Davis, L. Povinelli, N. Cox, A. Klimov. The Lancet, 2005

765 citations recorded by the source corpus.

Subfields: Critical Care and Intensive Care Medicine, Epidemiology

View Paper: https://www.semanticscholar.org/paper/811a8174dc5478f0fe1c22672b6f7b4211916425

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Yong‐Zhen Zhang
2. Edward C. Holmes

Citations in the corpus

• Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. (2006, neutral): “5 (5-28) Arizona 14/14 24 ( 1-87) California 6/7 6 ( 1-28) Colorado 6/6 25.”
• The Evolution and Emergence of RNA Viruses (2009, background): “Although the S31N mutation could confer suffi cient selective advantage to facilitate its spread in parts of South-east Asia where over-the-counter drug use is relatively common (Bright et al. 2005), such direct selection pressure cannot apply to most nations, including the USA, where the use of ada”